Favorable Outcome in Patients with Acute Myelogenous Leukemia with the Nucleophosmin Gene Mutation Autografted after Conditioning with High-Dose Continuous Infusion of Idarubicin and Busulfan

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 1018-1024

  Ferrara, Felicetto ^a   Izzo, Tiziana ^a   Criscuolo, Clelia ^a   Riccardi, Cira ^a   Muccioli, Giada ^b   Viola, Assunta ^a   Pane, Fabrizio ^b   Palmieri, Salvatore ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acute myeloid leukemia; Autologous transplantation; High dose idarubicin; NPM1 mutations

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; BUSULFAN; CD135 ANTIGEN; CIPROFLOXACIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; AUTOGRAFT; CANDIDIASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXON; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953612369     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.011     Document Type: Article

References (36)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004, 5:443-450.
2. Shipley J.L., Butera J.N. Acute myelogenous leukemia. Exp Hematol 2009, 37:649-658.
3. Ferrara F., Palmieri S., Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008, 66:181-193.
4. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
5. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92. 2322-2233.
6. Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18:115-136.
7. Farag S.S., Archer K.J., Mrozek K., et al. Pretreatment cytogenetcs add to other prognostic factors predicting complete remission and long term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
8. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
9. Dohner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloidleukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
10. Mrozèk K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
11. Rau R., Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009, 27:171-181.
12. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
13. Becker H., Marcucci G., Maharry K., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B Study. J Clin Oncol 2009 Dec 21, [Epub ahead of print].
14. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009, 385-395.
15. Hamadani M., Awan F.T., Copelan E.A. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2008, 14:556-567.
16. Ferrara F., Palmieri S., De Simone M., et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005, 128:234-241.
17. Ferrara F., Palmieri S., Pedata M., et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol Oncol 2009, 27:40-45.
18. Ferrara F., Mele G., Palmieri S., et al. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol 2009, 27:198-202.
19. Tarsitano M., Palmieri S., Ferrara F., Riccardi C., Cavaliere M.L., Vicari L. Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet 2009, 195:164-167.
20. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
21. Ferrara F., Morabito F., Martino B., et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000, 18:1295-1300.
22. Ferrara F., Palmieri S., Pollio F., et al. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant 2006, 12:981-986.
23. Roti G., Rosati R., Bonasso R., et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn 2006, 8:254-259.
24. Ferrara F., D'Arco A.M., De Simone M., et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005, 90:776-784.
25. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
26. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
27. Falini B., Sportoletti P., Martelli M.P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009, 21:573-581.
28. Falini B., Bolli N., Liso A., et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009, 23:1731-1743.
29. Schneider F., Hoster E., Unterhalt M., et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009, 113:5250-5253.
30. Cilloni D., Messa F., Rosso V., et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia 2008, 22:1234-1240.
31. Palmieri S., Ferrara F., Leoni F., et al. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol 2007, 25:1-5.
32. Fornari A., Piva R., Chiarle R., Novero D., Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. Hematol Oncol 2009, 27:161-170.
33. Hsu F.Y., Zhao Y., Anderson W.F., Johnston P.B. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 2007, 25:240-248.
34. Fernandez H.F., Sun Z., Yao X., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.
35. Löwenberg B., Ossenkoppele G.J., van Putten W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
36. Feller N., Schuurhuis G.J., van der Pol M.A., et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003, 17:68-75.